BioCentury
ARTICLE | Financial News

Onyx spinout Kezar raises $23M in series A

June 17, 2015 1:01 AM UTC

Kezar Life Sciences Inc. (South San Francisco, Calif.), a newco that houses assets spun out from the Onyx Pharmaceuticals Inc. subsidiary of Amgen Inc. (NASDAQ:AMGN), raised $23 million in a series A round. Investors included Morningside Venture; Cormorant Asset Management; EcoR1 Capital; 9W Capital Management; Omega Funds; Aju IB Investment; and undisclosed private investors. Onyx will license its immunoproteasome IP to Kezar and holds an undisclosed minority stake in the newco. ...